Q-Line Biotech (NSE:QLINE) Other Current Assets: ₹790 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
14 GF Score
Price ₹531.80
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech Other Current Assets?

Q-Line Biotech NSE:QLINE -1.12% 14 Other Current Assets is ₹790 Mil as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Q-Line Biotech's other current assets for the quarter that ended in Mar. 2025 was ₹790 Mil.

Q-Line Biotech's quarterly other current assets increased from Mar. 2023 (₹361 Mil) to Mar. 2024 (₹657 Mil) and increased from Mar. 2024 (₹657 Mil) to Mar. 2025 (₹790Mil).

Q-Line Biotech's annual other current assets increased from Mar. 2023 (₹361 Mil) to Mar. 2024 (₹657 Mil) increased from Mar. 2024 (₹657 Mil) to Mar. 2025 (₹790 Mil).


Q-Line Biotech Other Current Assets Related Terms


Q-Line Biotech Other Current Assets Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech Other Current Assets Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
Other Current Assets
360.92 657.05 789.91

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
Other Current Assets 360.92 657.05 789.91
NSE:QLINE
14GF Score
Q-Line Biotech Ltd NSE:QLINE
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-Line Biotech Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of ₹790 Mil mean?
Q-Line Biotech (NSE:QLINE) has a Other Current Assets of ₹790 Mil as of Mar. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Q-Line Biotech.
Is Q-Line Biotech's Other Current Assets too high?
Q-Line Biotech's current Other Current Assets is ₹790 Mil. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Other Current Assets compare to ABT and SYK?
Q-Line Biotech's Other Current Assets of ₹790 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Medical Devices & Instruments company?
A good Other Current Assets depends on the Medical Devices & Instruments industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Q-Line Biotech. Q-Line Biotech's current Other Current Assets is ₹790 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Other Current Assets of ₹790 Mil. The current Other Current Assets is ₹790 Mil. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Other Current Assets is ₹790 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score

Get the complete analysis for NSE:QLINE

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹531.80
Price